Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

NCT00970502 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Cancer of the Pharynx
Cancer of the Larynx
Cancer of the Neck
Paranasal Sinus Neoplasms
Cancer of the Head

Interventions

DRUG: erlotinib + celecoxib

Sponsor

Johnny Kao